Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with camrelizumab and apatinib in advanced hepatocellular carcinoma
ChiCTR2000034155Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: median overall survival. Started Jun 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000034155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034155.